Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance and affects 2%-8% of all pregnancies. Among other complications, GDM can lead to the development of type 2 diabetes mellitus (DM 2) in both mother and child. Peroxisome proliferator-activated receptors (PPARs) are major regulators of glucose and lipid metabolism. Furthermore, PPARs are mediators of inflammation and angiogenesis and are involved in the maternal adaptational dynamics during pregnancy to serve the requirements of the growing fetus. PPARs were originally named for their ability to induce hepatic peroxisome proliferation in mice in response to xenobiotic stimuli. The expression of three PPAR isoforms, alpha, beta/delta, and gamma, have been described. Each of them is encoded by different genes; however, they share 60%-80% homology in their ligand-binding and DNAbinding domains. PPARs are involved in trophoblast differentiation, invasion, metabolism, and parturition and are expressed in invasive extravillous trophoblast and villous trophoblast cells.
INTRODUCTION
To date, 48 known nuclear hormone receptors [1] have been described, which are members of the nuclear receptor superfamily and can be categorized by their sequence homology. In detail, peroxisome proliferator-activated receptors (PPARs), vitamin D receptor, and thyroid receptors belong to subfamily 1 (thyroid hormone receptor-like), whereas retinoid X receptor is part of subfamily 2 (retinoid X receptor-like).
Nuclear hormone receptors are located in the cell nucleus and act as transcription factors [2] [3] [4] . Unlike steroids, which bind their DNA response elements as homodimers [5] , nuclear hormone receptors are able to form either homodimers or heterodimers [6] . Nonsteroidal lipophilic ligands can bind and activate the nuclear hormone receptors. Retinoid X receptor, PPARs, vitamin D receptor, and thyroid receptor share a similar protein structure for ligand binding, DNA binding, dimerization, and transcriptional regulation.
Posttranscriptionally, all nuclear hormone receptors are regulated by phosphorylation [7] . In this context, PPAR seems to be the most promiscuous nuclear hormone receptor, as its ligand-binding pocket is capable of binding a variety of different ligands [8] . Over the past few years, a number of research endeavors and clinical trials focused on the development of highly targeted therapeutic strategies to induce diseasespecific responses by regulating nuclear hormone receptor superfamily members [1] .
Hence, it is not surprising that different ligands of nuclear hormone receptors are already utilized in pharmacological drugs. To date, they account for 13% of U.S. Food and Drug Administration-approved drugs [9] . To date, the insulinsensitizing drug thiazolidinediones (TZD) is one of the bestknown nuclear hormone receptor ligands and resembles the natural PPAR ligand structure [10] . The most utilized TZDs, ciglitazone, pioglitazone, and rosiglitazone (TZD-R), improve insulin sensitivity and thereby control blood glucose levels.
During pregnancy, dynamic physiologic, metabolic, and immunologic adaptations are required to ensure fetal development and maternal well-being. Many of the metabolic adaptations are mediated by PPARs [11, 12] . Dysregulation of PPARs may result in diseases such as gestational diabetes mellitus (GDM). This pregnancy-associated disease has a high incidence not only in Western Europe but also among women all over the world and implicates a lifelong risk for both mother and child to subsequently develop type 2 diabetes mellitus (DM 2), as well as metabolic syndrome with reduced life span. Therefore, disease-specific treatment of GDM may be highly beneficial not only in reducing pregnancy complications but also in diminishing the individual and economic burden associated with metabolic syndrome later in life. Furthermore, a significant association between GDM and preeclampsia has been observed [13] , and insulin resistance during early pregnancy increases the risk for preeclampsia in the second and third trimesters [14] . Hence, therapeutic approaches to reduce insulin resistance during early pregnancy may result in lower risk of not only pregnancy-induced hypertension but also cardiovascular diseases later in life [15] . To date, no targeted therapeutic interventions to address this problem are available, much less tested in pregnant women.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
Three PPAR isoforms are known to date, PPARA (PPARa, NR1C1), PPARD (b/d, NR1C2), and PPARC (c, NR1C3) [16] . It should be noted that PPARB and PPARD are often interchangeably used or referred to as PPARb/d, as both were identified at almost the same time and subsequently described as closely related in humans and Xenopus [17] . PPARA and PPARG have been identified as key regulators of cellular differentiation processes and anti-inflammatory regulation, whereas PPARD has also been associated with modulation of immune response [18] . PPARG consists of four different mRNA isoforms, PPARG1, PPARG2, PPARG3, and PPARG4 [19] . The isoforms PPARG1, PPARG3, and PPARG4 encode the same protein but differ in their activation function 1 structure [19] . PPARG2 cDNA encodes an additional 30 amino acids N-terminal to the first ATG codon of PPARG1 and reveals a different 5 0 untranslated sequence [20, 21] . PPARG1, PPARG12, and PPARG13 are expressed in adipose tissue, and PPARG1 and PPARG2 are additionally found in muscles and PPARG1 at lower levels in liver and heart [22] . In addition to its presence in adipose tissue, PPARG3 was identified in colon and macrophages [23, 24] . PPARG4 was also found in macrophages [25] .
Whereas PPARA is expressed in the liver, kidney, and heart, PPARD is ubiquitously expressed [23] . PPARG regulates adipogenesis and intracellular insulin signaling processes [26] and thereby controls glucose homeostasis. PPARG has also been associated with cell metabolism, immune responses, and carcinogenesis [27] .
The main natural ligands of PPARs are the intermediate and end products of fatty acids and sterol metabolic pathways [28] . These include fatty acids, eicosanoids, components of oxidized low-density lipoproteins (LDLs), and oxidized alkyl phospholipids such as lysophosphatidic acid and nitrolinoleic acid [29, 30] (Table 1 and Fig. 1 ).
During human pregnancy, the expression of PPARs initially increases in gestational tissues. Interestingly, once labor commences, the expression of PPARs decreases [31] . PPARA and PPARD are primarily expressed in the placenta, amnion, and decidua [31] , and PPARD is further expressed in human umbilical endothelial cells [32] .
To date, the role of PPARA during implantation remains unknown, whereas PPARD seems to have a central role in implantation and embryo development [33] . PPARD downregulates the gene expression of 11beta-hydroxysteroid dehydrogenase type 2, an enzyme involved in cortisol metabolism, in human trophoblast cells [34] . The key PPAR during pregnancy appears to be PPARG, as it influences trophoblast differentiation, invasion, metabolism, and parturition. It is detectable in invasive extravillous trophoblast and villous trophoblast. As pregnancy progresses, PPARG is further found in the anchoring villi, amnion, and chorion, and in the third trimester PPARG is expressed by the syncytiotrophoblasts [35] [36] [37] .
Lipid peroxide and plasma triglyceride concentrations increase during pregnancy. Additionally, LDLs are oxidized [38] and present in extravillous trophoblast. Oxidized LDLs inhibit extravillous trophoblast cell invasion [39] . Examples of oxidized LDLs are 9-hydroxy-octadedienoic and 13-hydroxyoctadedienoic acid [40] . Oxidized LDLs are ligands for PPARG. Associated PPARG activation results in an increase in human chorionic gonadotropin production [41] in the trophoblast. PPARG activation by agonists such as 15d-J 2 or oxidized LDL inhibits trophoblast invasion [37] , and it has been shown that 15d-J 2 also induces apoptosis in trophoblasts [42] . Furthermore, PPARG is capable of suppressing inflammatory responses in gestational tissue [43] by downregulating mediators such as cytokines [44] and nitric oxide [45] .
Findings from recent investigations suggest that PPARD agonists (as GW501516) may be used to treat multiple aspects of the metabolic syndrome and DM 2, including visceral obesity, dyslipidemia, insulin resistance, and vascular inflammation [46] . In vivo studies [46] [47] [48] have shown that GW501516 attenuates weight gain and insulin resistance in mice fed high-fat diets by elevating the expressions of genes that promote lipid catabolism and mitochondrial uncoupling in skeletal muscle, thus increasing beta-oxidation of fatty acids in skeletal muscle. PPARD agonists also inhibit lipopolysaccharide-inducible genes such as Ptgs2 (cyclooxygenase 2) and Induction of glucose uptake [30] PPARs AND GESTATIONAL DIABETES Nos2 (inducible nitric oxide synthase) in murine peritoneal macrophages. Also, PPAR-like ligands, TZDs, are widely used in women with polycystic ovary syndrome. Investigations have demonstrated the benefit of TZDs in the regulation of ovarian function in patients with polycystic ovary syndrome, especially in women with treatment resistance to metformin [49] . Besides their ability to affect insulin sensitivity, TZDs are known for their immune regulatory abilities (i.e., dampening of inflammation). Hence, the therapeutic spectrum of TZDs may be extended to include an additional patient population, women with endometriosis. However, to date only case series have reported benefits of TZDs in the treatment of endometriosis [50] .
PPARs IN ANIMAL MODELS
Various animal models for the investigation of PPAR function are available to date. The use of gain-of-function and loss-of-function mouse models has provided valuable insights into the context of reproduction and gestational diabetes. These mouse models include knockout (KO) of gene expression, conditional null mice in which PPAR expression is eliminated in specific tissues or at specific life stages, mice constitutively expressing PPARs, and ''humanized'' mice that express the human isoform rather that the endogenous mouse gene [51] . A summary of the animal models available is given in Table 2 .
Ppara KO mice (official symbol, Ppara tm1Gonz ) do not reveal obvious defects at birth, and the mice are viable and fertile and generally appear healthy as adults [52] , which prompted the notion that PPARA is not essentially required for successful reproduction. However, because adult Ppara KO mice were shown to accumulate lipids in the liver, develop obesity in later years [53] , and exhibit prolonged inflammatory responses [54] , PPARA may be a redundant system if reproduction is initiated early. However, disturbed pregnancies, which are associated with increased maternal age, may be attributable to PPARA-dependent pathways.
Uterine PPARD expression occurs during embryonic implantation, and it has been hypothesized that PPARD acts synergistically with cyclooxygenase-2-derived prostacyclin in promoting vascular permeability, thereby facilitating implantation [55] . In mice lacking PPARD, placental defects are predominant, which results in considerable frequency of fetal loss after implantation and small placentas, along with delayed maturation of surviving embryos [56] [57] [58] . Also, a lack of placental giant cell differentiation, associated with abnormal vascular development, Knock in A mutation (S112A) was induced to prevent PPARG phosphorylation Mendelian frequency of offspring genotypes [106] No changes in weight and adipose mass No prenatal lethality Preservation of insulin sensitivity PPARs AND GESTATIONAL DIABETES has been described in Ppard KO mice (official symbol, Ppard tm1.1Rev ), which may result in decreased levels of pregnancy-relevant hormones such as proliferin or progestins [57] . Surprisingly, surviving Ppard KO offspring largely become healthy fertile adults, which are slightly runted compared with Ppard wild-type mice. Strikingly, fetal lethality in Ppard KO depends on the mouse strain, with a high frequency seen in inflammation-prone mice such as C57BL/6 [59] .
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PPARG is detectable in abundance in adipose tissue and (although at lower expression) in cells of the innate and adaptive immune system, epithelial cells, and smooth muscle cells [60, 61] . Furthermore, PPARG has been suggested to modulate adipocyte differentiation [62] and insulin sensitization [10, 63] . The high expression of PPARG in atherosclerotic lesions has fostered intensive research efforts to identify possible roles of PPARG in regulating cholesterol influx, thereby promoting the development of atherosclerosis [64, 65] . During reproduction, PPARG is involved in secretion of reproductive hormones by trophoblasts, and it has been suggested to negatively regulate trophoblast invasion into the decidua [66, 67] .
Disruption of the Pparg gene causes embryonic lethality due to placental dysfunction [68, 69] . The use of genetically engineered mice lacking the Pparg gene also led to the confirmation that Pparg regulates terminal epithelial differentiation of trophoblast cells such as the labyrinthine syncytiotrophoblast and spongiotrophoblast cells. Also, fetal blood vessels do not penetrate, and the labyrinthine layer fails to form properly in Pparg KO mice (official symbol, Pparg tm1Rev ) [69] . Furthermore, placentas from Pparg KO mice have been described to lack lipid droplets [70] , which may lead to undernutrition of the fetus. Strikingly, a functional link between the placenta and the developing fetal heart was further confirmed in the Pparg KO mice, which provides a rationale for the origins of congenital cardiomyopathies [69] .
Because the embryonic lethality of the Pparg KO mice restricted the use of these mice in certain experimental settings, a conditional Pparg gene KO mouse was generated [71] . The availability of this conditional KO mouse then led to the recognition that PPARG has a critical role in the regulation of cholesterol homeostasis by controlling the expression of a network of genes that mediate cholesterol efflux from cells and its transport in plasma. Furthermore, these mice revealed that adipocyte PPARG is required for normal adiposity and insulin sensitivity in fat and liver but not in muscle [59, 72] .
Overall, the use of genetically engineered mice in the context of PPAR research has led to the realization that PPARA, PPARD, and PPARG are expressed in the embryo at early developmental stages. Especially, the availability of Ppard and Pparg KO mice was pivotal in confirming their role during blastocyst implantation, placental development, and survival of the embryo. Herein, PPARG has been shown to be critical for embryonic implantation, as it regulates storage of lipids and affects cells of the innate immune system that are necessary for placental development, through which it may dampen inflammation and avoid fetal loss. To date, insight about the risk for GDM or preeclampsia in these Ppar KO mice is largely lacking.
Animal investigations showed that PPARG has a critical role in the regulation of cholesterol homeostasis by controlling the expression of a network of genes that mediate cholesterol efflux from cells and its transport in plasma [59, 72] . Furthermore, these mice revealed that adipocyte PPARG is required for normal adiposity and insulin sensitivity in fat and liver but not in muscle. In addition, dexamethasone treatment (5 days) of nonpregnant rats augmented glucose-stimulated insulin secretion at high glucose levels. This effect was in contrast to PPARA activation. Pregnancy-induced changes in glucose-stimulated insulin secretion were opposed by PPARA activation at Day 19 of pregnancy [73] . Suwaki et al. [11] examined the expression of PPARG in placentas of diabetic pregnant mice. In these mouse placentas, the expression of PPARG significantly increased compared with that in normal placentas. Hyperglycemic conditions significantly enhanced the expression of PPARG [11] . Furthermore, a synthetic PPAR antagonist, the phosphonophosphate SR-202, has been shown to decrease PPARs, along with a reduction of adipocyte hypertrophy and insulin resistance [74] . Such novel and highly targeted approaches have potential for use in the treatment of GDM. 
CLINICAL APPLICATION
During normal pregnancy, physiologic changes occur with regard to maternal lipid and glucose metabolism. Glucose serves as a predominant energy source for the developing fetus; therefore, a continuous demand on the mother to provide this substrate is notable [75] , resulting in frequent hypoglycemia and postprandial hyperglycemia during normal pregnancy [75, 76] . Pathological conditions of energy metabolism, as seen in GDM, are often present in individuals with obesity or preexisting diabetes. Furthermore, GDM is associated with maternal and fetal morbidity such as maternal birth injuries, macrosomia, brachial plexus palsy, and others.
Catalano et al. [77] questioned whether decreased adipose tissue insulin receptor expression in women with GDM likely contributes to reduced lipolysis with ongoing gestation. Decreased expression of PPARG and its target genes may be part of the pathophysiologic mechanisms to accelerate fat catabolism and thereby ensure fetal nutrition in late gestation.
Each PPAR subtype regulates a different metabolic pathway, and the agonists of each of the PPAR subtypes have distinct effects and some undesired adverse effects such as weight gain, hepatotoxicity, and heart failure [78] . PPARG activators such as pioglitazone and TZD-R are widely used in patients with DM 2 [79] . Besides their role in targeting metabolism, pleitropic functions such as antiproliferative and anti-inflammatory effects have been described [50] . In contrast, TZDs can promote weight gain and peripheral edema and increase the risk of myocardial ischemia (especially TZD-R versus placebo) [80, 81] . Nevertheless, large clinical trials failed to associate TZD-R with increased cardiovascular risk [82] .
To reduce adverse effects of PPARG agonists, selective PPARG modulators with insulin-sensitizing activity and lower stimulation of adipogenesis have been developed. Halofenate and PA-082, new selective PPARG modulators, were shown to selectively regulate the expression of multiple PPARGresponsive genes in 3T3-L1 adipocytes and to have acute antidiabetic properties in diabetic ob/ob mice [83] . Most recently, data from SYNCHRONY, a phase II dose-ranging trial of aleglitazar (a dual PPARA/G agonist) in patients with DM 2 became available that indicate a good risk-benefit profile [84] . The risk of TZD administration during pregnancy has yet to be carefully evaluated, and a safety profile of TZD in pregnancy remains to be established.
Another type of PPAR agonist is emerging, namely, the PPAR panagonists, which are capable of activating all three PPAR subtypes and can likely elicit several effects such as insulin resistance, obesity, dyslipidemia, and hypertension. Currently, GW-677954, PLX-204, GW625019, LY-465608, DRF-11605, CS-204, and DRL-11605 are under investigation [85] .
Differentiation of adipocytes and trophoblasts is induced by ligand-induced PPARG activation via 15-deoxy D 12,14 prostaglandin J 2 (15d-J 2 ). Furthermore, 15d-J 2 is capable of downregulating nitric oxide production. This is remarkable because nitric oxide is upregulated in term placentas from patients with diabetes [45] . Jawerbaum et al. [45] showed that 15d-J 2 levels were increased in gestational and pregestational women with diabetes compared with control subjects. This may be indicative of a regulatory pathway associated with the attempt to restore homeostasis. However, exogenous application of 15d-J 2 leads to downregulated nitric oxide production only in control placentas and placentas of women with pregestational symptoms and not in placentas of women with GDM. Because exogenous 15d-J 2 application influenced nitric oxide production in placentas of women with pregestational symptoms, 15d-J 2 may have the potential to improve placental and fetal development in the setting of GDM.
Sulfonylurea agents such as gliumepiride and glibenclamide represent the most widely used oral hypoglycemic drugs and are known to exhibit PPARG1 agonist activity [86] . Langer et al. [87] showed that glyburide and insulin are equally effective in the treatment of GDM and that no significant differences were observed among the study group in terms of metabolic, respiratory, and neonatal intensive care unit efficacy. With regard to the placental barrier, investigations of glyburide and glipizide found little or no transfer, whereas metformin and TZD-R cross readily [88] . However, there was no evidence for teratogenic effects of glyburide, glipizide, metformin, or TZD-R in animal investigations [88] . Glyburide was safe and efficacious in patients with GDM, although 16%-19% of patients failed to achieve optimal glucose control [88] .
Possible candidate genes predisposing for GDM include PPARs. Clinical studies [89, 90] focusing on PPARG2 polymorphisms revealed a link between the polymorphism and alterations in body mass index and insulin sensitivity. However, Tok et al. [91] observed no effects of the PPAR-G2 Pro12A1a polymorphism on glucose metabolism in healthy pregnant women or women with GDM, although the polymorphism was associated with weight gain. This was further confirmed by Shaat et al. [92] , who investigated the PPAR-G2 Pro12A1a polymorphism and the PPARG coactivator-1alpha (PGC-1) in 1881 unrelated pregnant Scandinavian women. Leipold et al. [93] were also unable to show an association of the PGC-1 polymorphism with GDM. This indicates that PPAR polymorphisms may be insufficient to predict individuals at risk of developing GDM. Also, the functional correlate of PPAR polymorphisms (e.g., their effect on glucose regulation) remains to be determined.
CONCLUSIONS
Given the multiple variables involved in GDM representing a clustering of modifiable risk factors predisposing pregnant women to develop GDM, new approaches are necessary to manage the many possible lifelong complications for both mother and child. PPARs are an attractive and still relatively untapped target for drug development based on their ability to regulate glucose homeostasis and lipogenesis. Considering that candidate genes for GDM include PPARs, together with the availability of new generations of receptor-specific PPAR modulators, future research is urgently required to test the safety and efficacy of PPAR ligands in improving placental and fetal development in settings such as women with GDM.
